



Preclinical Development Plan

For a new Chemical Entity, Vaccine, or Biologic

SRI International (formerly Stanford Research Institute) has extensive experience in the preparation of Preclinical Development Plans (PDPs) that provide a detailed path from discovery to clinic. Originally created for SRI's PharmaSTART[®] consortium with several top academic institutions, the PDP was later adopted by the NIH to support the NIH RAID program.

Preclinical Development Plans prepared by SRI were initially used to determine if potential academic investigators had a viable path to the clinic for their therapeutic drug candidates. SRI has subsequently expanded this program and now prepares PDPs for a variety of NIH institutes to support the preclinical development of a wide variety of therapeutics. SRI PDPs have become the gold standard for development plans for therapeutics and vaccines.

SRI prepares PDPs for an extensive client base including: start-up companies, small and virtual companies, entrepreneurs, academic researchers, foundations, and venture capital and other funding sources. The PDP is an invaluable tool for resource planning, timing, fund raising, and execution of a successful development strategy.

For more information on how a Preclinical Development Plan can accelerate your development program, click [here](#).

Or Contact us at:

SRI International
Biosciences Division
333 Ravenswood Avenue
Menlo Park, CA 94043

650-859-3000
biosciences@sri.com
<http://www.sri.com/biosciences>